Market revenue in 2023 | USD 19.8 million |
Market revenue in 2030 | USD 32.1 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Mirabegron |
Fastest growing segment | Neuromodulation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anticholinergics, Mirabegron, Botox, Neuromodulation, Other |
Key market players worldwide | Pfizer Inc, AbbVie Inc, Astellas Pharma Inc, Medtronic PLC, Sumitomo Pharma Co Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd, Hisamitsu Pharmaceutical Co Inc, Par Pharmaceutical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to overactive bladder treatment market will help companies and investors design strategic landscapes.
Mirabegron was the largest segment with a revenue share of 27.78% in 2023. Horizon Databook has segmented the Argentina overactive bladder treatment market based on anticholinergics, mirabegron, botox, neuromodulation, other covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina overactive bladder treatment market, including forecasts for subscribers. This country databook contains high-level insights into Argentina overactive bladder treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account